Q-omics provides the consensus-scored ZNF525 profile across patient tissues and cancer cell-line models. ZNF525 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF525 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, ZNF525 RNA expression shows 20,771 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, BLCA, and KIRP as cancer lineages where ZNF525 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF525 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF525 survival associations across molecular data types. ZNF525 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF525 RNA expression–survival associations across cancer types. High ZNF525 expression shows unfavorable associations in CESC, LUSC, LGG and ACC, but favorable associations in KIRC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF525 RNA expression.
This table summarizes ZNF525 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF525. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF525 shows lower tumor expression in THCA and higher tumor expression in BLCA, LUAD, LUSC, STAD and LIHC. The BLCA box plot shows higher ZNF525 RNA expression in tumor versus normal tissue (log2 FC = +1.548, t-test p < 0.001).
This table shows molecular features associated with ZNF525 in patient tissues and cancer cell lines. In patient samples, ZNF525 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF525 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
